Welcome to our dedicated page for Quantum X Labs SEC filings (Ticker: QXL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quantum X Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quantum X Labs's regulatory disclosures and financial reporting.
Quantum X Labs Inc. director Yoresh Eliyahu exercised a pre-funded warrant to acquire 88,675 shares of common stock. The warrant had a stated exercise price of $0.0001 per share and was exercised on a cashless basis, so no shares were withheld for taxes or payment.
After the exercise, Eliyahu held 435,951 shares of Quantum X Labs common stock directly and 2,518 shares indirectly through Yoresh Capital Ltd. The filing shows an exercise-and-hold pattern, with no open-market sales reported in this transaction.
QUANTUM X LABS INC. Co-CEO Baranes Yakov exercised a pre-funded warrant to acquire 246,387 shares of common stock on May 31, 2026. The shares were obtained at an exercise price of $0.0001 per share on a cashless basis, and no shares were withheld for taxes or fees.
Following the exercise, his directly held common stock position increased to 353,177 shares. The corresponding pre-funded warrant for 246,387 underlying shares was fully exercised and now shows zero remaining derivative balance.
QUANTUM X LABS INC. director Ronen Rosenbloom filed an initial Form 3, which is the required statement of beneficial ownership when an insider first becomes subject to reporting rules. This filing lists him as a director but does not report any share transactions or derivative positions.
QUANTUM X LABS INC. reported that Tzedef Kineret filed an initial Form 3 as a director of the company. This filing is a required ownership disclosure for new insiders and does not show any stock purchases, sales, option exercises, or other transactions.
QUANTUM X LABS INC. Co-CEO Baranes Yakov has filed an initial Form 3 to report his holdings in the company. He reports direct ownership of 106,790 shares of common stock.
He also holds a Pre-Funded Warrant that is exercisable into 246,387 shares of common stock at an exercise price of $0.0001 per share. According to the disclosure, these Pre-Funded Warrants will not expire until they are exercised in full. The filing does not show any new purchases or sales, only the positions he already holds.
Quantum X Labs Inc. filed a report describing the launch of its new 50+ physical qubit neutral-atom quantum computing platform that uses proprietary atom cooling and dynamically reconfigurable optical tweezer arrays. This architecture is designed to support rapid, high-fidelity qubit loading, extended coherence times, and high-performance Rydberg-mediated two-qubit gates.
The company states that its qubit strategy aims to reach thousands of qubits by the end of H1 2027. This roadmap relies on integrating a pending patented deep transformer decoder (US12294387B2), an AI-based error correction system coupled to the neutral-atom control stack to enable low-latency, syndrome-guided error correction and a pathway toward fault-tolerant logical qubit operations.
According to the disclosure, the platform is intended to strengthen Quantum X Labs’ broader quantum portfolio in computing, software and simulation, and sensing, and is aimed at advanced applications such as aerospace and defense, clinical trials, process optimization, nuclear energy, pharmaceuticals, and quantum cybersecurity.
Quantum X Labs Inc. appointed Yakov Baranes as co-Chief Executive Officer, effective May 18, 2026, alongside existing CEO Amihay Hadad, who will continue in a co-CEO structure. Baranes has 11 years of strategy experience across industries and government entities and has led Quantum X Labs Ltd., the company’s Israeli quantum-focused subsidiary, since March 2025.
Under a new agreement effective June 1, 2026, Baranes will receive a base salary of NIS 36,000 + VAT per month as co-CEO, plus NIS 24,000 + VAT per month for services to Quantum Israel, with eligibility for board-determined bonuses. The agreement is open-ended with a 60-day termination notice by either party, and immediate termination for cause is permitted.
In the March 2026 acquisition of Quantum Israel, Baranes, who previously held 32,647 shares (approximately 5.54%) of Quantum Israel, received 103,373 shares of common stock and pre-funded warrants to purchase 246,387 shares of Quantum X Labs common stock and may receive up to an additional 703,710 shares or pre-funded warrants upon achieving specified milestones.
Quantum X Labs Inc. Amendment No. 1 to a Schedule 13G/A reports that L.I.A. Pure Capital Ltd. beneficially owns 1,332,366 shares of common stock. The filing states this represents 9.99% of the class based on 13,336,392 shares outstanding as of the date hereof. The filing also notes that 7,079,877 Shares may be acquired within 60 days through exercise of warrants, subject to a blocker provision that limits exercise to prevent beneficial ownership above 4.99%. The amendment is signed by Kfir Silberman, Chief Executive Officer on 05/15/2026.
Capitalink Ltd. amended its Schedule 13G to report beneficial ownership in X Labs Inc. The filing states Capitalink beneficially owns 667,034 shares, representing 4.99% of X Labs' 13,336,392 shares outstanding used for the calculation. The filing counts 38,000 additional shares issuable upon exercise of warrants within 60 days and notes a 44,283-share warrant subject to a blocker provision.
X Labs Inc. filed an amendment to a Schedule 13G/A reporting beneficial ownership of 1,179,230 shares of Common Stock, representing 8.65% of the class. The filing states this percentage was calculated based on 13,336,392 shares outstanding as of the date hereof.
The filing explains the 1,179,230 figure consists of 879,230 Shares plus 300,000 Shares issuable upon conversion of a convertible loan. It also discloses additional potential shares tied to warrants: 44,283 Shares exercisable within 60 days and 300,000 Shares issuable upon conversion-related warrants, each subject to a blocker provision limiting exercises above 4.99%.